Yes. There is rightfully a lot of excitement around CAR-T, but we have a ways to go before we know if this will be a cure and for which group of patients.

The Price of Remission When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked ...

I have written many healthcare stories, but never before have I written about my own health. I decided to do so after learning one of my drugs costs nearly $1,000 a pill and just 25 cents to make. What I found was an incredible story of discovery and exploitation. www.propublica.org/article/revl...

Cancer research, long protected, feels ‘devastating’ effects under Trump Cancer research has had bipartisan support. But Trump administration budget cuts and delays threaten to reverse progress of recent years, experts say.

The momentum from dramatic improvements in cancer treatment over the past two decades is now at risk www.statnews.com/2025/03/24/t...

Endo’s End Around: How One of the Nation’s Largest Opioid Makers Escaped a $7 Billion Federal Penalty For a decade, the Justice Department delayed a winning criminal case against Philadelphia-based Endo Health Solutions. That allowed the company to vastly expand its narcotics empire and execute a corp...

Who wins when a major opioid manufacturer settles federal claims of reckless behavior? The lawyers ($350 million) and company executives ($95 million in bonuses). Losers? Opioid victims (about $1,000 per victim). Read the details here - www.propublica.org/article/endo...

OxyContin Maker Explored Expansion Into “Attractive” Anti-Addiction Market Secret portions of a lawsuit allege that Purdue Pharma, controlled by the Sackler family, considered capitalizing on the addiction treatment boom — while going to extreme lengths to boost sales of its...

In wake of McKinsey's $650 million settlement with the government for its role advising opioid companies, read our story from nearly six years ago on how the company helped Purdue Pharma www.propublica.org/article/oxyc...